{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:09:37Z","timestamp":1780448977401,"version":"3.54.1"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.2169\/internalmedicine.0444-17","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T18:25:29Z","timestamp":1528223129000},"page":"3135-3139","source":"Crossref","is-referenced-by-count":24,"title":["The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature"],"prefix":"10.2169","volume":"57","author":[{"given":"Akifumi","family":"Tabei","sequence":"first","affiliation":[{"name":"Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuharu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Ikeuchi","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Nakasatomi","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Sakairi","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoriaki","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Maeshima","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[{"name":"Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Hirato","sequence":"additional","affiliation":[{"name":"Department of Pathology, Gunma University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Nojima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Nephrology, Japan Red Cross Maebashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiju","family":"Hiromura","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget 6: 3479-3492, 2015.","DOI":"10.18632\/oncotarget.2980"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54: 139-148, 2016.","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8: 49, 2017.","DOI":"10.3389\/fphar.2017.00049"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kourie HR, Awada G, Awada AH. Learning from the &quot;tsunami&quot; of immune checkpoint inhibitors in 2015. Crit Rev Oncol Hematol 101: 213-220, 2016.","DOI":"10.1016\/j.critrevonc.2016.03.017"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Izzedine H, Gueutin V, Gharbi C, et al. Kidney injuries related to ipilimumab. Invest New Drugs 32: 769-773, 2014.","DOI":"10.1007\/s10637-014-0092-7"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Thajudeen B, Madhrira M, Bracamonte E, Cranmer LD. Ipilimumab granulomatous interstitial nephritis. Am J Ther 22: e84-e87, 2015.","DOI":"10.1097\/MJT.0b013e3182a32ddc"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis 68: 287-291, 2016.","DOI":"10.1053\/j.ajkd.2016.02.057"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90: 638-647, 2016.","DOI":"10.1016\/j.kint.2016.04.008"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Jung K, Zeng X, Bilusic M. Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrol 17: 188, 2016.","DOI":"10.1186\/s12882-016-0408-2"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Murakami N, Borges TJ, Yamashita M, Riella LV. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin Kidney J 9: 411-417, 2016.","DOI":"10.1093\/ckj\/sfw024"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Belliere J, Meyer N, Mazieres J, et al. Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer 115: 1457-1461, 2016.","DOI":"10.1038\/bjc.2016.358"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Escandon J, Peacock S, Trabolsi A, Thomas DB, Layka A, Lutzky J. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. J Immunother Cancer 5: 3, 2017.","DOI":"10.1186\/s40425-016-0205-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Uchida A, Watanabe M, Nawata A, et al. Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings. CEN Case Rep 6: 169-174, 2017.","DOI":"10.1007\/s13730-017-0269-y"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372: 2521-2532, 2015.","DOI":"10.1056\/NEJMoa1503093"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373: 123-135, 2015.","DOI":"10.1056\/NEJMoa1504627"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372: 2018-2028, 2015.","DOI":"10.1056\/NEJMoa1501824"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122-133, 2013.","DOI":"10.1056\/NEJMoa1302369"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Berney-Meyer L, Hung N, Slatter T, Schollum JB, Kitching AR, Walker RJ. Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury? Nephrology (Carlton) 19: 359-365, 2014.","DOI":"10.1111\/nep.12226"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Zhao L, David MZ, Hyjek E, Chang A, Meehan SM. M2 macrophage infiltrates in the early stages of ANCA-associated pauci-immune necrotizing GN. Clin J Am Soc Nephrol 10: 54-62, 2015.","DOI":"10.2215\/CJN.03230314"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686, 2004.","DOI":"10.1016\/j.it.2004.09.015"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Nikolic-Paterson DJ, Wang S, Lan HY. Macrophages promote renal fibrosis through direct and indirect mechanisms. Kidney Int Suppl (2011) 4: 34-38, 2014.","DOI":"10.1038\/kisup.2014.7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Palmer MB, Vichot AA, Cantley LG, Moeckel GW. Quantification and localization of M2 macrophages in human kidneys with acute tubular injury. Int J Nephrol Renovasc Dis 7: 415-419, 2014.","DOI":"10.2147\/IJNRD.S66936"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ikezumi Y, Suzuki T, Karasawa T, et al. Identification of alternatively activated macrophages in new-onset paediatric and adult immunoglobulin A nephropathy: potential role in mesangial matrix expansion. Histopathology 58: 198-210, 2011.","DOI":"10.1111\/j.1365-2559.2011.03742.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/21\/57_0444-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T23:35:03Z","timestamp":1571441703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/21\/57_0444-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":23,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0444-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,1]]}}}